Glutamine metabolites promote the progression of cervical cancer by inducing M2 macrophage polarization
Pathology - Research and Practice · 2026
DOI: 10.1016/j.prp.2025.156348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Tingting Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Glutamine, Tumor-Associated Macrophages, Macrophages. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
BACKGROUND: Tumour-associated macrophages (TAMs) within the tumour microenvironment play crucial roles in tumour initiation, invasion, and metastasis. While glutamine synthetase (GS) is expressed predominantly in the tumour stroma, particularly in TAMs, the role of glutamine metabolism in regulating TAM polarization and function in cervical cancer (CC) remains poorly understood. This study aims to clarify this role and its implications for cancer progression. METHODS: CD68 and GS expression in cervical tissues was detected using immunofluorescence staining. The effects of glutamine metabolism on TAM polarization were investigated via RTqPCR, flow cytometry, Western blotting and NAA treatment analyses. CCK8, colony formation, and Transwell assays were conducted to determine the effects of MSO-treated macrophages on tumour cell proliferation, migration, and invasion. RESULTS: We observed a significant increase in GS expression in TAMs within cervical cancer (CC) tissues, particularly in M2-like TAMs. Glutamine synthesized by TAMs with high GS expression was found to increase the proliferation, migration, and invasion of CC cells. Inhibition of GS in TAMs notably reduced their tumour-promoting effects. Additionally, the byproducts of glutamine metabolism in CC cells contributed to the polarization of TAMs towards the M2 phenotype. This polarization was completely abrogated when SNAT1, a key glutamine transporter, was inhibited in CC cells. CONCLUSIONS: Our findings demonstrate that glutamine synthesized by TAMs with high GS expression promotes tumour progression in CC. Furthermore, glutamine byproducts produced by CC cells induce TAM polarization towards the M2 phenotype, suggesting crucial metabolic crosstalk between tumour cells and macrophages that supports tumour progression. These results highlight the potential of targeting glutamine metabolism to modulate TAM function and inhibit tumour growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Electronic address: sfj296@163.com.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Hubei Province
Zitieren
APA
Liu, T., Zhang, L., Li, Y., Liao, W., Deng, J., Liang, H., & Shen, F. (2026). Glutamine metabolites promote the progression of cervical cancer by inducing M2 macrophage polarization. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156348
Vancouver
Liu T, Zhang L, Li Y, Liao W, Deng J, Liang H, et al. Glutamine metabolites promote the progression of cervical cancer by inducing M2 macrophage polarization. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2025.156348
BibTeX
@article{Liu2026,
author = {Liu, Tingting and Zhang, Lanyue and Li, Yang and Liao, Wenxin and Deng, Juexiao and Liang, Hua and Shen, Fujin},
title = {Glutamine metabolites promote the progression of cervical cancer by inducing M2 macrophage polarization},
journal = {Pathology - Research and Practice},
year = {2026},
doi = {10.1016/j.prp.2025.156348}
}
EUVIMED